Antigen-presenting nanoparticles for in vivo CAR T cell engineering.

In vivo cell engineering enables chimeric antigen receptor (CAR) production directly within the body. Most in vivo CAR approaches target broad T cell populations. However, antigen-presenting nanoparticles could be used to engineer specific T cell subsets, leveraging the phenotypic and functional properties of the cells for T cell therapy.